Vyvanse Capsules
PDF Leaflet Revision Date: 14 November 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients > 13 years.
Dosage (summary)
Starting dose: 30 mg once daily; max dose: 70 mg/day.
Onset of Action / Duration
Onset: 1-2 hours, Duration: up to 14 hours.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients > 55 years
Pregnancy & Breastfeeding
Not recommended in pregnancy; contraindicated in breastfeeding.
Key Drug Interactions
- MAOIs
- Serotonergic medications
- Antihypertensives
Contraindications
- Hypersensitivity to sympathomimetics
- Cardiovascular disease
- Glaucoma
- Severe depression
Common side effects
- Insomnia
- Decreased appetite
- Dry mouth
- Headache
- Irritability
Counselling Points
- Take in the morning
- Monitor for weight loss
- Avoid afternoon doses to prevent insomnia
Serious warnings
- Potential for abuse and dependence
- Cardiovascular events
- Psychiatric symptoms
Important Disclaimer
The Vyvanse Capsules professional information leaflet below is the property of Takeda and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
